Physician profile
Anthony Bashall
NPI 1033290440
$96,912.51
in general payments reported to CMS, 2019-2025
28 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $54.59 · 2021: $22.79 · 2022: $1,078 · 2023: $1,173 · 2024: $33K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Honoraria: $13K · Food and Beverage: $5,464 · Travel and Lodging: $3,220 · Education: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,295.69 |
| Honoraria | $12,600.00 |
| Food and Beverage | $5,464.43 |
| Travel and Lodging | $3,219.53 |
| Education | $628.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63,248.79 | 2022-2025 | Wegovy, Ozempic |
| Lexicon Pharmaceuticals, INC. | $14,319.84 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,106.95 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $5,386.06 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $688.14 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Novartis Pharmaceuticals Corporation | $603.77 | 2019-2025 | |
| Amgen INC. | $473.20 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $450.59 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $343.00 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $227.32 | 2019-2025 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $213.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.65 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $181.22 | 2022-2024 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $79.99 | 2025 | Uptravi, Opsumit |
| Abbott Laboratories | $58.89 | 2024-2025 | Mitraclip |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $47.37 | 2023 | Korsuva, Veltassa |
| Madrigal Pharmaceuticals | $39.14 | 2025 | Rezdiffra |
| Impulse Dynamics (USA) INC. | $38.99 | 2022 | |
| Cvrx, INC. | $37.50 | 2023-2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $28.36 | 2023 | Injectafer |
| Kerecis Limited | $25.20 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Amarin Pharma, INC. | $21.64 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $19.79 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $17.37 | 2023 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $14.89 | 2024 | Arcalyst |
| Mayne Pharma Commercial LLC | $14.51 | 2019 | |
| Scpharmaceuticals INC. | $14.16 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.70 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Bashall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.